MedRegen is proud to announce that the FDA has approved the IND applications for a combined phase 1/2 clinical trial with MRG-001 for the treatment of COVID-19 disease.
MedRegen is proud to announce that the FDA has approved the IND applications for a combined phase 1/2 clinical trial with MRG-001 for the treatment of COVID-19 disease.
Optimized by Seraphinite Accelerator